Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2018)
Abstract
Tazemetostat, a potent, selective, oral EZH2 inhibitor has shown antitumor activity in a phase 1 study that included NHL patients with mutated (mt) or wild-type (wt) EZH2 tumors, providing rationale for further investigation.
MoreTranslated text
Key words
Non-Hodgkin Lymphoma,Follicular lymphoma,EZH2,EZH2 inhibitor
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined